TRT(600085)2024-10-29 08:58Revenue and Profit Performance - Revenue for the third quarter reached RMB 4.06 billion, a year-on-year increase of 2.42%[2] - Net profit attributable to shareholders of the listed company for the third quarter was RMB 329.09 million, a year-on-year decrease of 18.57%[2] - Total revenue from the beginning of the year to the end of the reporting period was RMB 13.82 billion, a year-on-year increase of 0.72%[4] - Net profit attributable to shareholders of the listed company from the beginning of the year to the end of the reporting period was RMB 1.35 billion, a year-on-year decrease of 2.92%[4] - Total revenue for the first three quarters of 2024 reached 13.82 billion RMB, a slight increase from 13.72 billion RMB in the same period of 2023[17] - Net profit for the first three quarters of 2024 was 2.34 billion RMB, compared to 2.63 billion RMB in 2023[17] - Net profit attributable to parent company shareholders decreased to 1.35 billion yuan from 1.39 billion yuan, with minority shareholders' profit also dropping to 633.60 million yuan from 782.62 million yuan[19] - Total comprehensive income decreased to 1.97 billion yuan from 2.26 billion yuan, with parent company owners' share at 1.34 billion yuan and minority shareholders' share at 627.00 million yuan[20] - Basic earnings per share decreased to 0.984 yuan from 1.014 yuan[20] Asset and Liability Changes - Total assets as of the end of the reporting period were RMB 31.24 billion, a year-on-year increase of 3.82%[3] - Equity attributable to shareholders of the listed company as of the end of the reporting period was RMB 12.98 billion, a year-on-year decrease of 0.61%[3] - Total assets as of September 30, 2024, stood at 31.24 billion RMB, up from 30.09 billion RMB at the end of 2023[16] - Total liabilities as of September 30, 2024, were 10.73 billion RMB, compared to 9.83 billion RMB at the end of 2023[16] - Cash and cash equivalents decreased to 10.94 billion RMB as of September 30, 2024, from 12.13 billion RMB at the end of 2023[14] - Accounts receivable increased to 1.59 billion RMB as of September 30, 2024, from 1.06 billion RMB at the end of 2023[14] - Inventory rose to 10.79 billion RMB as of September 30, 2024, from 9.34 billion RMB at the end of 2023[14] - Long-term investments increased to 76.53 million RMB as of September 30, 2024, from 18.24 million RMB at the end of 2023[14] - Ending cash and cash equivalents balance decreased to 10.89 billion yuan from 12.82 billion yuan[22] Shareholder and Investment Information - The largest shareholder is China Beijing Tongrentang (Group) Co., Ltd., holding 719,308,540 shares, accounting for a significant portion of the total shares[9] - China Securities Finance Corporation holds 41,033,808 shares, representing a notable stake in the company[9] - Hong Kong Securities Clearing Company Limited holds 32,871,772 shares, indicating substantial foreign investment[9] - The top 10 shareholders collectively hold a significant portion of the company's shares, with no known relationships or concerted actions among them[9] - The company's shares are widely held by various funds, including the China Industrial and Commercial Bank Co., Ltd. - China Europe Medical Health Fund, holding 39,610,214 shares[9] - The company's shares are also held by major index funds such as the China Construction Bank Co., Ltd. - E Fund CSI 300 Healthcare ETF, holding 10,709,993 shares[11] - The company's shares are actively traded, with significant holdings by funds like the China Industrial and Commercial Bank Co., Ltd. - Huaxia CSI 300 ETF, holding 5,529,476 shares[11] - The company's shares are also held by the China Bank Co., Ltd. - Harvest CSI 300 ETF, holding 5,368,456 shares[11] - The company's shares are subject to margin trading and securities lending, with some shareholders participating in these activities[10] - The company's shares are held by a diverse group of investors, including both domestic and international entities, indicating broad market interest[12] Cost and Expense Analysis - The decrease in net profit was mainly due to the increase in raw material costs, particularly the rise in prices of traditional Chinese medicinal materials[4] - Operating costs for the first three quarters of 2024 were 11.48 billion RMB, up from 11.09 billion RMB in 2023[17] - Research and development expenses for the first three quarters of 2024 were 139.09 million RMB, down from 150.40 million RMB in 2023[17] - Interest expenses increased to 97.54 million yuan from 66.11 million yuan, while interest income decreased to 124.54 million yuan from 158.29 million yuan[19] - Other income rose significantly to 81.76 million yuan from 25.58 million yuan, and investment income turned positive at 66.37 million yuan compared to a loss of 1.05 million yuan[19] Cash Flow and Financial Activities - Cash flow from operating activities turned negative at -52.55 million yuan, compared to a positive 2.39 billion yuan in the previous year[21] - Cash flow from investing activities worsened to -223.42 million yuan from -83.07 million yuan[22] - Cash flow from financing activities improved slightly to -846.47 million yuan from -1.17 billion yuan[22] - Net increase in cash and cash equivalents was -1.13 billion yuan, a significant decrease from the previous year's 1.19 billion yuan increase[22] Other Financial Metrics - Accounts receivable increased by 50.64% compared to the beginning of the year, mainly due to the rolling use of customer credit limits[6] - Long-term equity investments increased by 319.49% compared to the beginning of the year, primarily due to the transfer of shares in a subsidiary[7] - Other income increased by 219.61% year-on-year, mainly due to the recognition of additional tax deductions for advanced manufacturing enterprises[7]